Diabetes news - the latest biotech news from Labiotech.eu

FDA approves type 2 diabetes drug for children 10 and older

Jim Cornall — Thu, 22 Jun 2023 08:22:47 +0000

The U.S. Food and Drug Administration (FDA) has approved Jardiance (empagliflozin) 10 mg and 25 mg tablets to lower blood sugar along with diet and exercise in children 10 years and older with type 2 diabetes, Boehringer Ingelheim and Eli Lilly and Company have announced. “As the burden of type 2 diabetes increases among young […]

The post FDA approves type 2 diabetes drug for children 10 and older appeared first on Labiotech.eu.

© Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

Quell in potential $2B AstraZeneca cell therapy deal

Jim Cornall — Fri, 09 Jun 2023 08:33:35 +0000

Quell Therapeutics Ltd, a developer of engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, has entered into a collaboration, exclusive option and license agreement with AstraZeneca to develop, manufacture and commercialize autologous, engineered Treg cell therapies for two autoimmune disease indications. “We are extremely pleased to have AstraZeneca on […]

The post Quell in potential $2B AstraZeneca cell therapy deal appeared first on Labiotech.eu.

Researchers identify gene expression signature to predict progression of type 1 diabetes

Jim Cornall — Tue, 30 May 2023 09:41:02 +0000

Researchers from Turku Bioscience Centre and InFLAMES Flagship at the University of Turku in Finland, have identified a gene expression signature that can predict the progression of type 1 diabetes.The study, led by Laura Elo and Riitta Lahesmaa, aimed to identify transcriptional changes associated with disease progression in patients with recent-onset type 1 diabetes. The […]

The post Researchers identify gene expression signature to predict progression of type 1 diabetes appeared first on Labiotech.eu.

DiogenX raises €27.5M for “breakthrough” diabetes treatment

Jim Cornall — Fri, 12 May 2023 10:50:28 +0000

DiogenX, a biotech company focused on regenerating insulin-producing beta cells for the treatment of diabetes, has announced the successful completion of a €27.5 million ($30 million) Series A financing round. New investors Roche Venture Fund, Eli Lilly and Company and Omnes joined this round alongside existing investors Boehringer Ingelheim Venture Fund (BIVF), JDRF T1D Fund, […]

The post DiogenX raises €27.5M for “breakthrough” diabetes treatment appeared first on Labiotech.eu.

Aspect and Novo Nordisk working on bioprinted tissue for diabetes and obesity

Jim Cornall — Thu, 13 Apr 2023 10:00:00 +0000

Aspect Biosystems and Novo Nordisk A/S are set to collaborate on developing bioprinted tissue therapeutics to replace, repair, or supplement biological functions inside the body with the aim of delivering a new class of disease-modifying treatments for diabetes and obesity. The collaboration will leverage Aspect’s bioprinting technology and Novo Nordisk’s background in stem cell differentiation […]

The post Aspect and Novo Nordisk working on bioprinted tissue for diabetes and obesity appeared first on Labiotech.eu.

Sanofi adds diabetes drug through Provention Bio $2.9B acquisition

Jim Cornall — Mon, 13 Mar 2023 16:30:21 +0000

Sanofi and Provention Bio, Inc., a U.S.-based, publicly traded biopharmaceutical company focused on intercepting and preventing immune-mediated diseases including type 1 diabetes (T1D), have entered into an agreement under which Sanofi has agreed to acquire Provention Bio, Inc., for $25.00 per share in cash, representing an equity value of approximately $2.9 billion. The transaction adds […]

The post Sanofi adds diabetes drug through Provention Bio $2.9B acquisition appeared first on Labiotech.eu.

Researchers develop treatment for vancomycin-resistant bacteria

Jim Cornall — Thu, 09 Mar 2023 17:33:04 +0000

Researchers from several institutions have developed a treatment for bacteria resistant to vancomycin, which is also known as vancomycin-resistant Enterococcus faecalis (VRE). The group consists of researchers from the Antimicrobial Resistance (AMR) Interdisciplinary Research Group (IRG) at Singapore-MIT Alliance for Research and Technology (SMART), MIT’s research enterprise in Singapore, in collaboration with Singapore Centre for […]

The post Researchers develop treatment for vancomycin-resistant bacteria appeared first on Labiotech.eu.

Antiverse identifies therapeutic antibodies targeting GPCRs

Jim Cornall — Thu, 02 Mar 2023 11:15:48 +0000

Antiverse Ltd has announced the successful identification of functional antibody clusters targeting two G-protein-coupled receptors (GPCRs), both displaying versatile binding profiles and nanomolar affinity. Antiverse, which was featured as one of our five Welsh biotech startups making waves in 2023, also announced it has raised $3 million funding, which will enable in-house development of the […]

The post Antiverse identifies therapeutic antibodies targeting GPCRs appeared first on Labiotech.eu.

HKUMed develops nanoparticle-based targeted drug delivery system

Jim Cornall — Tue, 21 Feb 2023 12:12:32 +0000

A research team from LKS Faculty of Medicine, the University of Hong Kong (HKUMed) has developed thyroid hormone (TH) – encapsulated nanoparticles modified with adipose-homing peptide, which selectively transport TH to adipose tissues. The researchers say this will advance the treatment of obesity-related medical complications with TH by overcoming its severe adverse effects caused by […]

The post HKUMed develops nanoparticle-based targeted drug delivery system appeared first on Labiotech.eu.

Can CRISPR correct type 2 diabetes gene?

Jim Cornall — Tue, 21 Feb 2023 11:58:17 +0000

Swedish researchers have identified 395 genes that are differently expressed in people with type 2 diabetes. One of these (PAX5) has proven to be very strongly associated with impaired insulin secretion. Now, researchers want to investigate if it is possible to use the genetic CRISPR/Cas9 scissors to correct the gene’s activity. The research team’s scientific […]

The post Can CRISPR correct type 2 diabetes gene? appeared first on Labiotech.eu.

Antibody candidate for treating serious liver disease

Jim Cornall — Tue, 07 Feb 2023 10:14:35 +0000

There is currently no drug for treating non-alcoholic fatty liver disease, which affects many people with type 2 diabetes and which can result in other serious liver diseases. However, a new study led by researchers from Karolinska Institutet in Sweden has identified a drug candidate for the treatment of fatty liver. The preclinical study, published […]

The post Antibody candidate for treating serious liver disease appeared first on Labiotech.eu.

Psoriasis drug may help treat type 1 diabetes

Jim Cornall — Fri, 27 Jan 2023 11:15:52 +0000

A large clinical study is now beginning on an approved drug for treating psoriasis. The drug will be tested on patients who were recently diagnosed with type 1 diabetes. The theory is that the drug could preserve the patient’s remaining insulin production. Many hospitals in Sweden are participating in the project, which is funded by […]

The post Psoriasis drug may help treat type 1 diabetes appeared first on Labiotech.eu.

Beyond Biotech podcast 31: Orgenesis, Phacilitate, Terumo, University of Birmingham, VIVEBiotech

Jim Cornall — Fri, 27 Jan 2023 11:04:12 +0000

Phacilitate’s Advanced Therapies Week took place last week in Miami Beach, Florida. This week, we speak with the organizers, as well as some of the companies in attendance. Our guests are Kim Barnes, EVP, Phacilitate; Kathie Schneider, director and global commercial lead at Terumo; Vered Caplan, CEO, Orgenesis; Ivan Wall, head of the Centre for […]

The post Beyond Biotech podcast 31: Orgenesis, Phacilitate, Terumo, University of Birmingham, VIVEBiotech appeared first on Labiotech.eu.

Orbsen Therapeutics happy with interim diabetic kidney disease study results

Jim Cornall — Thu, 26 Jan 2023 11:23:40 +0000

Orbsen Therapeutics Limited has announced what it says are encouraging headline interim results from the EU Horizon 2020-funded NEPHSTROM clinical trial for diabetic kidney disease. NEPHSTROM is a randomized, double-blind, placebo-controlled phase 1/2a, trial evaluating the safety, tolerability and preliminary efficacy of an off-the-shelf allogeneic bone marrow-derived mesenchymal stromal cell immunotherapy, ORBCEL, in adult study […]

The post Orbsen Therapeutics happy with interim diabetic kidney disease study results appeared first on Labiotech.eu.

First patient treated in Atrogi type 2 diabetes clinical study

Jim Cornall — Thu, 26 Jan 2023 08:54:11 +0000

Atrogi AB, an early-stage Swedish pharma company, has announced that the first patient has been enrolled in a phase 1a/b study. Atrogi’s drug candidate, ATR-258 is a first in class novel b2 adrenoceptor agonist with a unique mechanism of action for the treatment of type 2 diabetes and comorbidities. This approach is supported by data […]

The post First patient treated in Atrogi type 2 diabetes clinical study appeared first on Labiotech.eu.

What’s in store for biotech in 2023?

Jim Cornall — Wed, 11 Jan 2023 08:34:21 +0000

Perhaps 2022 will best be remembered in the life science industry for the return of many of the face-to-face events that fell by the wayside during the COVID-19 pandemic. It might have been a mixed year for biotech companies, but 2023 is a new year, with new challenges, but also new opportunities. So what do […]

The post What’s in store for biotech in 2023? appeared first on Labiotech.eu.

Aditxt forms Adimune to focus on immune modulation therapies

Jim Cornall — Wed, 04 Jan 2023 10:35:52 +0000

Aditxt, Inc., a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, has formed a U.S.-based subsidiary Adimune, Inc. The plan is to submit a clinical trial application (CTA) for its immunotherapeutic technology drug candidate, ADI-100 (ADI). The CTA will request approval for Adimune to conduct the […]

The post Aditxt forms Adimune to focus on immune modulation therapies appeared first on Labiotech.eu.

Pfizer diabetes and obesity study triggers Sosei Heptares windfall

Jim Cornall — Wed, 21 Dec 2022 09:30:38 +0000

Sosei Group Corporation has been notified by Pfizer that the first subject in a phase 2 clinical trial has been dosed with Pfizer’s candidate PF-07081532. This triggers a $10 million payment to Sosei Heptares. PF-07081532 is a once-daily, next-generation oral small molecule GLP-1 receptor agonist in development for the treatment of type 2 diabetes and obesity. […]

The post Pfizer diabetes and obesity study triggers Sosei Heptares windfall appeared first on Labiotech.eu.

Watch: Sernova’s Cell Pouch System tackles diabetes

Jim Cornall — Tue, 20 Dec 2022 19:40:15 +0000

Sernova Corp. is a Canadian-based clinical-stage biotechnology company that is developing its Cell Pouch System. This is a novel implantable and scalable medical device with immune protected therapeutic cells, for the treatment of chronic diseases such as insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. On implantation, the Cell Pouch forms a […]

The post Watch: Sernova’s Cell Pouch System tackles diabetes appeared first on Labiotech.eu.

Watch: Sigrid CEO talks about lifestyle diseases

Jim Cornall — Tue, 20 Dec 2022 13:57:01 +0000

Sigrid Therapeutics AB was founded in 2014 by Tore Bengtsson and Sana Alajmovic, with the vision of transforming the way modern day chronic lifestyle diseases are treated and prevented. The company’s research dates back to 2008 when Bengtsson and his research group at the Department of Molecular Biosciences at Stockholm University in Sweden made discoveries […]

The post Watch: Sigrid CEO talks about lifestyle diseases appeared first on Labiotech.eu.